Autonomic effects of selegiline: Possible cardiovascular toxicity in Parkinson's disease

Journal of Neurology Neurosurgery and Psychiatry

Volumn 63, Issue 2, 1997, Pages 228-234

  Churchyard, A ^a   Mathias, C J ^b,c   Boonkongchuen, P ^a   Lees, A J ^a,b  

^a UNIVERSITY COLLEGE LONDON   (United Kingdom)

^b NATIONAL HOSPITAL FOR NEUROLOGY AND NEUROSURGERY   (United Kingdom)

^c ST MARY S HOSPITAL   (United Kingdom)

Author keywords

Orthostatic hypotension; Parkinson's disease; Selegiline

Indexed keywords

AMINE OXIDASE (FLAVIN CONTAINING); AMPHETAMINE; ANTIPARKINSON AGENT; LEVODOPA; NORADRENALIN; SELEGILINE;

AGED; ARTICLE; AUTONOMIC DYSFUNCTION; CARDIOTOXICITY; CARDIOVASCULAR RESPONSE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG WITHDRAWAL; FEMALE; HEAD TILTING; HEART RATE; HUMAN; MALE; MORTALITY; MOTOR PERFORMANCE; NORADRENALIN BLOOD LEVEL; ORAL DRUG ADMINISTRATION; ORTHOSTATIC HYPOTENSION; PARKINSON DISEASE; PRIORITY JOURNAL; STANDING; UNCONSCIOUSNESS; UNITED KINGDOM;

EID: 0030879210     PISSN: 00223050     EISSN: None     Source Type: Journal    
DOI: 10.1136/jnnp.63.2.228     Document Type: Article

References (51)

1. Elsworth JD, Glover V, Reynolds GP, et al. Deprenyl administration in man: a selective monoamine oxidase B inhibitor without the "cheese effect". Psychopharmacol 1978;57:33-8.
2. Olanow CW. A rationale for monoamine oxidase inhibition as neuroprotective therapy for Parkinson's disease. Mov Disord 1993;8(suppl):S1-7.
3. The Parkinson Study Group. The effect of tocopherol and deprenyl on the progression of disability in early Parkinson's disease. N Engl J Med 1993;328:176-83.
4. Lees AJ. on behalf of the Parkinson's Disease Research Group of the UK. Comparison of therapeutic effects and mortality data of levodopa and levodopa combined with selegiline in patients with early, mild Parkinson's disease. BMJ 1995;311:1602-7.
5. Parkinson Study Group. Impact of deprenyl and tocopherol treatment on Parkinson's disease in DATATOP patients not requiring levodopa. Ann Neurol 1996;39:29-36.
6. Parkinson Study Group. Impact of deprenyl and tocopherol treatment on Parkinson's disease in DATATOP patients requiring levodopa. Ann Neurol 1996;39:37-15.
7. Birkmayer W, Riederer P, Ambrozi L, Youdim MBH. Implications of combined treatment with Madopar and L-deprenyl in Parkinson's disease. Lancet 1977;4:39-3.
8. Lees AJ, Kohout LJ, Shaw KM, et al. Deprenyl in Parkinson's disease. Lancet 1977;ii:791-5.
9. Reynolds GP, Elsworth JD, Blau K, et al. Deprenyl is metabolized to metamphetamine and amphetamine in man. Br J Clin Pharmacol 1978;6:542-15.
10. Gill JR, Mason DT, Bartter F. Effects of hydroxyamphetamine on the function of the sympathetic nervous system in normotensive subjects. J Pharmacol Exp Ther 1967;155: 288-95.
11. Cayanaugh JH, Griffith JD, Oates JA. Effect of amphetamine on the pressor response to tyramine: formation of p-hydroxynorephedrine. Clin Pharmacol Ther 1970;11:656-64.
12. Rangno RE, Kaufmann JS, Cavanaugh JH, et al. Effects of a false neurotransmitter, p-hydroxynorephedrine, on the function of adrenergic neurons in hypertensive patients. J Clin Invest 1973;52:952-60.
13. Martin WR, Sloan JW, Sapira JD, Jasinski DR. Physiologic, subjective and behavioural effects of amphetamine, metamphetamine, ephedrine, phenmetrazine and methylphenidate in man. Clin Pharmacol Ther 1971;12:245-60.
14. Knoll J. The possible mechanisms of action of (-)deprenyl in Parkinson's disease. J Neurol Trans 1978;43:177-98.
15. Simpson LL. Evidence that deprenyl, a type B monoamine oxidase inhibitor, is an indirectly acting sympathomimetic amine. Biochem Pharmacol 1978;27:1591-5.
16. Gibb, Lees AJ. The relevance of the Lewy body to the pathogenesis of idiopathic Parkinson's disease. J Neurol Neurosurg Psych 1988;51:745-52.
17. Mathias CJ, Bannister RB. Investigation of autonomic disorders. In: Bannister RB, Mathias CJ, eds. Autonomic failure. A textbook of clinical disorders of the autonomic nervous system. 3rd ed. Oxford: OUP,1992.
18. Mathias CJ, Bannister RB, Cortelli P, et al. Clinical, autonomic and therapeutic observations in two siblings with postural hypotension and sympathetic failure due to an inability to synthesize noradrenaline from dopamine because of a deficiency of dopamine beta hydroxylase. Q J Med 1990;75:617-33.
19. Mathias CJ. Disorders of the autonomie nervous system. In: Bradley EG, Daroff RB, Fenichel GM, Marsden CD, eds. Neurology in clinical practice. 2nd ed. Boston: Butterworth Heinemann, 1996;2:82,1953-81.
20. Hainsworth R. Syncope and fainting. In: Bannister RB, Mathias CJ, eds. Autonomic failure. A textbook of clinical disorders of the autonomic nervous system. 3rd ed. OUP, Oxford, 1992.
21. Rae-Grant A, Young GB, Spence JD. Monoamine oxidase inhibitors and sinemet in shy-drager syndrome. Neurology 1985;35:1085-6.
22. Turkka J, Suominen K, Tolonen U, et al. Effect of selegiline on cardiovascular autonomie responses in Parkinson's disease. Acta Neurol Scand 1996;94(suppl 167):22.
23. Sprangers RLH, Wesseling KH, Imholz ALT, Imholz BPM, Wieling W. Initial blood pressure fall on stand up and exercise explained by changes in total peripheral resistance. J Appl Physiol 1991;70:523-30.
24. Guyton AC. In: Human physiology and mechanisms of disease. 4th ed. Philadelphia: WB Saunders, 1987.
25. Ohama E, Ikuta F. Parkinson's disease: distribution of Lewy bodies and monoamine neuron system. Acta Neuropathol 1976;34:311-9.
26. Wakabayashi K, Takahashi H, Ohama E, Ikuta F. Parkinson's disease: an immunohistochemical study of Lewy body-containing neurons in the enteric nervous system. Acta Neuropathol 1990;79:581-3.
27. Gai WP, Geffen LB, Denoroy L, Blessing WW. Loss of C1 and C3 epinephrine-synthesizing neurons in the medulla oblongata in Parkinson's disease. Ann Neurol 1993;33:357-67.
28. Kopp N, Denoroy L, Tommasi M, et al. Increase in noradrenaline-synthesizing enzyme activity in medulla oblongata in Parkinson's disease. Acta Neuropathol 1982; 56:17-21.
29. Montastruc JL, Senard JM, Rascol O, Rascol A. Autonomic nervous system dysfunction and adrenoreceptor regulation in Parkinson's disease. Adv Neurol 1996;69:377-81.
30. McDaniel KD. Clinical pharmacology of monoamine oxidase inhibitors. Clin Neuropharmacol 1986;9:207-34.
31. Goldberg LI. Monoamine oxidase inhibitors. JAMA 1964; 190:132-8.
32. Sunderland T, Mueller EA, Cohen RM, et al. Tyramine sensitivity changes during deprenyl treatment. Psychopharmacol 1985;86:432-7.
33. Gelowitz DL, Richardson JS, Wishart TB, et al. Chronic 1-deprenyl or 1-amphetamine: equal cognitive enhancement, unequal MAO inhibition. Pharmacol Biochem Behav 1994;47:41-5.
34. Waldmeier PC, Felner AE. Deprenil: loss of selectivity for inhibition of B-type MAO after repeated treatment. Biochem Pharmacol 1978;27:801-2.
35. Ekstedt B, Magyar K, Knoll J. Does the B form selective monoamine oxidase inhibitor lose selectivity by long term treatment? Biochem Pharmacol 1979;28:919-23.
36. Riederer P, Youdim MBH, Rausch WD, et al. On the mode of action of 1-deprenyl in the human nervous central system. J Neurol Trans 1978;43:217-26.
37. Karoum F, Chuang LW, Eisler T, et al. Metabolism of (-) deprenyl to amphetamine and metamphetamine may be responsible for deprenyl's therapeutic benefit: a biochemical assessment. Ann Neurol 1982;32:503-9.
38. Fozard JR, Zreika M, Robin M, Palfreyman MG. The functional consequences of inhibition of monoamine oxidase type B: comparison of the pharmacological properties of 1-deprenyl and MDL 72145. Naunyn Schmiedebergs Arch Pharmacol 1985;331:186-93.
39. Okuda C, Segal DS, Kuczenski R. Deprenyl alters behaviour and caudate dopamine through an amphetamine-like action. Pharmacol Biochem Behav 1992; 43:1075-80.
40. Engberg G, Elebring T, Nissbrandt H. Deprenyl (selegiline), a selective MAO-B inhibitor with active metabolites;effects on locomotor activity, dopaminergic neurotransmission and firing rate of nigral dopamine neurons. J Pharmacol Exp Ther 1991;259:841-7.
41. Rosenberg DE, Wolbach AB, Miner EJ, Isbell H. Observations on direct and cross tolerance with LSD and d-amphetamine in man. Psychopharmacol 1963;5: 1-15.
42. Cheng HC, Long JP, Barfknecht CF, Nicholls DE. Cardiovascular effects of 2,5-dimethoxy-4-methylamphetamine. J Pharmacol Exp Ther 1973;186:345-54.
43. Wilson JM, Kalasinsky KS, Levey AI, et al. Striatal dopamine terminal markers in human, chronic metamphetamine users. Nat Med 1996;2:699-703.
44. Ricaurte GA, Seiden LS, Schuster CR. Further evidence that amphetamines produce long-lasting dopamine neurochemical deficits by destroying dopamine nerve fibres. Brain Res 1984;303:359-64.
45. Preston KL, Wagner GC, Schuster CR, Seiden LS. Further evidence that amphetamines produce long-lasting dopamine neurochemical deficits by destroying dopamine nerve fibres. Brain Res 1985;338:243-8.
46. Woolverton WL, Ricaurte GA, Forno LS, Seiden LS. Longterm effects of chronic metamphetamine administration in rhesus monkeys. Brain Res 1989;486:73-8.
47. Yu PH, Lai CT, Boulton AA. Selegiline may be toxic in presence of increased dopamine concentrations. Lancet 1996;312:703-1.
48. Brust JCM. In: Brust JCM, ed. Neurological aspects of substance abuse. London: Butterworth-Heinemann, 1993.
49. Davis PL, Stewart WB. The use of benzedrine sulfate in postencephalitic parkinsonism. JAMA 1938;110:1890-2.
50. Parkes JD, Tarsy D, Marsden CD, et al. Amphetamines in the treatment of Parkinson's disease. J Neurol Neurosurg Psychiatry 1975;35:232-7.
51. Anderson KE, Girdwood AC and Wilson JA. Stopping selegiline may lead to problems for patients. Lancet 1996;312: 702-3.